Screening sarcopenia through SARC-F in postmenopausal women: a single-center study from South America.

Objective: This study aimed to estimate the prevalence of postmenopausal women at high risk of sarcopenia and to compare their quality of life (QOL) with those at low risk using the SARC-F questionnaire. Methods: We performed a cross-sectional study of postmenopausal women who attended a menopause clinic in Colombia. The risk of sarcopenia was determined through the SARC-F questionnaire; a score ≥4 was considered high risk. The Menopause Rating Scale, the International Physical Activity Questionnaire, and the Short Physical Performance Battery (SPPB) tool were applied. Results: A total of 112 postmenopausal women with an average age of 68.4 ± 8.5 years were included. The prevalence of women at high risk of sarcopenia was 15.2% (n = 17) (95% confidence interval: 9.7; 23.0). Among the high-risk group there was a higher proportion of women with severe symptoms in the three domains when compared to the low-risk group (somatic 7% vs. 24%, psychological 15% vs. 44%, and urogenital 28% vs. 53%; p < 0.05). A tendency to a lower physical performance was found in the high-risk group (SPPB: 8 [interquartile range: 6-11] vs. SPPB: 10 [interquartile range: 8-11), p = 0.059). Conclusion: Our results suggest that women with high risk of sarcopenia have a poor QOL. The SARC-F questionnaire is a brief and non-invasive screening tool to detect postmenopausal women at high risk of sarcopenia.

Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years.

The objective of this study was to evaluate retrospectively the weight variation in long-term users of depot medroxyprogesterone acetate (DMPA) compared to users of the TCu380A intrauterine device (IUD). A cohort of 206 healthy women allocated in two groups of 103 women according to the contraceptive method used was evaluated through 5 years. Each user of DMPA was paired with an IUD user by age (+/- 1 year) and weight (+/- 1 kg) at the beginning of the study. Weight was evaluated yearly during 5 years. The mean age at the beginning of the study was 33.1 years in both groups, and the mean weight was 59.4 kg in the IUD users and 60.4 kg in the DMPA group. Both cohorts of women presented significant weight increase at the end of the 5 years of observation (p < 0.001). However, DMPA users presented higher weight increase when compared to IUD users from the second through the fifth year of observation. The DMPA users increased weight by 4.3 kg during the 5 years, and IUD users increased 1.8 kg. In conclusion, DMPA users had a significantly higher weight increase when compared to IUD users. In addition, this cohort of women increased weight throughout the 5 years with the use of DMPA or IUD.